[The pathogenesis of myasthenia gravis as an immunological problem].
D000305:Adrenal Cortex Hormones / Q000009:adverse effects / Q000627:therapeutic use; D000328:Adult; D000367:Age Factors; D000368:Aged; D000818:Animals; D000906:Antibodies / Q000032:analysis; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001323:Autoantibodies / Q000032:analysis; D001327:Autoimmune Diseases; D001798:Blood Proteins / Q000032:analysis; D003165:Complement System Proteins / Q000032:analysis; D005260:Female; D006168:Guinea Pigs; D006801:Humans; D008297:Male; D008875:Middle Aged; D009157:Myasthenia Gravis / Q000139:chemically induced / Q000145:classification / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology / Q000235:genetics / Q000276:immunology* / Q000601:surgery; D012377:Rodentia; D012737:Sex Factors; D009435:Synaptic Transmission; D013934:Thymectomy; D013950:Thymus Gland / Q000002:abnormalities / Q000166:cytology / Q000473:pathology; D013953:Thymus Neoplasms / Q000276:immunology
D000305:Adrenal Cortex Hormones; D000906:Antibodies; D000970:Antineoplastic Agents; D001323:Autoantibodies; D001798:Blood Proteins; D003165:Complement System Proteins
Die Pathogenese der Myasthenia gravis als immunologisches Problem.